4506 Sumitomo Pharma Co., Ltd. - Financial Results

About Information Provided on This Site

The information provided on our website 'Kabutan.com' is not intended to constitute investment solicitation or investment advisory services.
All investment decisions should be made at your own discretion and judgment.
The data on our website is provided by Tokyo Stock Exchange, Osaka Exchange, Nagoya Securities Exchange, JPX Market Innovation & Research, Japannext, and other sources.
Copyright of the Nikkei Stock Average belongs to Nikkei Inc. Stock price charts displayed on Kabutan.com are provided solely for the purpose of reviewing historical price movements of the securities.
These charts neither suggest nor guarantee future price movements of the securities and do not constitute recommendations to buy or sell.
In our financial results coverage, the term 'Surprise Results' identifies securities that demonstrate a significant degree of surprise in their earnings announcements.
This significance is quantitatively assessed based on multiple factors, including: the nature of the announcement (full-year or quarterly results); types of revisions (earnings or dividend forecasts); and numerical analysis comparing the announced results with both the company's previous forecasts and historical performance.
The 'Surprise Ranking' presents these results in order of their calculated surprise factor. Please note that neither these results nor rankings are intended to suggest or guarantee future performance of the listed securities, nor should they be construed as recommendations to buy or sell.

4506

TSE Prime

Sumitomo Pharma Co., Ltd.

571

JPY

-8

(-1.38%)

Dec 23, 3:30 pm JST

3.64

USD

Dec 23, 1:30 am EST

Result

ー

PTS

outside of trading hours

568.9

Dec 23, 5:42 pm JST

Summary Chart Historical News Financial Result

Current Period Guidance

Annual

Result

Guidance History

Growth Rate

Profitability

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Mar, 2021	515,952	71,224	77,851	56,219	141.5	28	May 12, 2021	IFRS
Mar, 2022	560,035	60,234	82,961	56,413	142.0	28	May 13, 2022	IFRS
Mar, 2023	555,544	-76,979	-47,920	-74,512	-187.6	21	May 15, 2023	IFRS
Mar, 2024	314,558	-354,859	-323,114	-314,969	-792.8	0	May 14, 2024	IFRS
Mar, 2025 Guidance	338,000	0	ー	-16,000	-40.3	0	May 14, 2024	IFRS
YoY	+7.5%	－	－	+94.9%	+94.9%

Revision Direction	Revision Date	Revenue	Operating Profit	Ordinary Profit	Net Profit	Revised Dividend	Accounting Standards
Mar, 2020	May 10, 2019	460,000	69,000	72,000	49,000	28	IFRS
	Jul 29, 2019	475,000	88,000	91,000	36,000	28	IFRS
	Jan 30, 2020	475,000	75,000	78,000	31,000	28	IFRS
-	Apr 28, 2020	482,700	83,200	ー	40,800	28	IFRS
- Results	May 13, 2020	482,732	83,239	83,947	40,753	28	IFRS
Mar, 2021	May 13, 2020	Available in future release
	Jul 30, 2020
	Oct 28, 2020
	Feb 12, 2021
	Apr 23, 2021
Results	May 12, 2021
Mar, 2022	May 12, 2021
	Jan 31, 2022
	Apr 28, 2022
Results	May 13, 2022
Mar, 2023	May 13, 2022
	Oct 31, 2022
	Jan 31, 2023
	Mar 3, 2023
	Apr 28, 2023
Results	May 15, 2023
Mar, 2024	May 15, 2023
	Jan 31, 2024
	Apr 30, 2024
Results	May 14, 2024
Mar, 2025	May 14, 2024	338,000	0	ー	-16,000	0	IFRS

Fiscal Year	Revenue	YoY	Operating Profit	YoY	Ordinary Profit	YoY	Adj. EPS	YoY
Mar, 2000	155,496	+6.2	Available in future release
Mar, 2001	158,873	+2.2
Mar, 2002	164,117	+3.3
Mar, 2003	172,161	+4.9
Mar, 2004	170,842	-0.8
Mar, 2005	173,899	+1.8
Mar, 2006	245,783	+41.3
Mar, 2007	261,213	+6.3
Mar, 2008	263,992	+1.1
Mar, 2009	264,037	0.0
Mar, 2010	296,261	+12.2
Mar, 2011	379,513	+28.1
Mar, 2012	350,395	-7.7
Mar, 2013	347,724	-0.8
Mar, 2014	387,693	+11.5
Mar, 2015	371,370	-4.2
Mar, 2016	403,206	+8.6
Mar, 2017	411,638	+2.1
Mar, 2018	466,838	+13.4
Mar, 2019	459,267	-1.6
Mar, 2020	482,732	+5.1
Mar, 2021	515,952	+6.9
Mar, 2022	560,035	+8.5
Mar, 2023	555,544	-0.8
Mar, 2024	314,558	-43.4
Mar, 2025 Guidance	338,000	+7.5	0	+100.0	ー	+100.0	-40.3	+94.9

Fiscal Year	Revenue	Operating Profit	Operating Profit Margin	ROE	ROA	Total Asset Turnover Ratio	Adj. EPS
Mar, 2023	555,544	-76,979	-14	-14.69	-6.10	0.45	-187.6
Mar, 2024	314,558	-354,859	-113	-111.93	-30.85	0.31	-792.8
Mar, 2025 Guidance	338,000	0	ー	-14.01	-2.00	0.42	-40.3

All-Time High

	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS
Record	560,035	88,173	84,866	56,413	142.0
Fiscal Year	Mar, 2022	Mar, 2018	Mar, 2018	Mar, 2022	Mar, 2022

Second Half

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Oct - Mar, 2021	266,305	12,662	33,695	19,963	50.3	14	May 13, 2022	IFRS
Oct - Mar, 2022	236,255	-48,064	-68,954	-67,229	-169.2	7	May 15, 2023	IFRS
Oct - Mar, 2023	161,916	-268,361	-266,987	-247,228	-622.3	0	May 14, 2024	IFRS
Oct - Mar, 2024 Guidance	157,251	8,179	ー	16,229	40.9	0	Oct 30, 2024	IFRS
YoY	-2.9%	－	－	－	－

Cash Flow

Annual

Fiscal Year	Operating Profit	Fee Cash Flow	Operating Cash Flow	Investing Cash Flow	Financial Cash Flow	Cash & Equivalents	Cash Ratio	Accounting Standards
Mar, 2022	60,234	12,961	31,239	-18,278	-21,426	202,984	15.52	IFRS
Mar, 2023	-76,979	64,356	11,937	52,419	-146,817	143,478	12.64	IFRS
Mar, 2024	-354,859	-208,857	-241,893	33,036	77,851	29,047	3.20	IFRS

Actual Performance and Financial Trends

Accumulated Results 2nd Quarter

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Progress Rate vs. First Half	Announce	Accounting Standards
Apr - Sep, 2022	319,289	-28,915	21,034	-7,283	-18.3	ー	Oct 31, 2022	IFRS
Apr - Sep, 2023	152,642	-86,498	-56,127	-67,741	-170.5	ー	Oct 31, 2023	IFRS
Apr - Sep, 2024	180,749	-8,179	-32,406	-32,229	-81.1	ー	Oct 30, 2024	IFRS
YoY	+18.4%	+90.5%	+42.3%	+52.4%	+52.4%

Quarterly Results

Result

Growth Rate

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Operating Profit Margin	Announce	Accounting Standards
Oct - Dec, 2022	140,976	11,138	-18,842	-11,219	-28.2	7.9	Jan 31, 2023	IFRS
Jan - Mar, 2023	95,279	-59,202	-50,112	-56,010	-141.0	-62.1	May 15, 2023	IFRS
Apr - Jun, 2023	75,686	-51,567	-31,052	-38,865	-97.8	-68.1	Jul 31, 2023	IFRS
Jul - Sep, 2023	76,956	-34,931	-25,075	-28,876	-72.7	-45.4	Oct 31, 2023	IFRS
Oct - Dec, 2023	82,386	-31,247	-49,064	-49,967	-125.8	-37.9	Jan 31, 2024	IFRS
Jan - Mar, 2024	79,530	-237,114	-217,923	-197,261	-496.5	-298.1	May 14, 2024	IFRS
Apr - Jun, 2024	90,675	-3,105	17,203	15,937	40.1	-3.4	Jul 31, 2024	IFRS
Jul - Sep, 2024	90,074	-5,074	-49,609	-48,166	-121.2	-5.6	Oct 30, 2024	IFRS
YoY	+17.0%	+85.5%	-97.8%	-66.8%	-66.8%

Fiscal Year	Revenue	YoY	Operating Profit	YoY	Ordinary Profit	YoY	Adj. EPS	YoY
Oct - Dec, 2019	126,414	+4.7	Available in future release
Jan - Mar, 2020	125,715	+11.9
Apr - Jun, 2020	133,857	+13.9
Jul - Sep, 2020	127,641	+12.8
Oct - Dec, 2020	133,264	+5.4
Jan - Mar, 2021	121,190	-3.6
Apr - Jun, 2021	131,196	-2.0
Jul - Sep, 2021	162,534	+27.3
Oct - Dec, 2021	138,342	+3.8
Jan - Mar, 2022	127,963	+5.6
Apr - Jun, 2022	159,876	+21.9
Jul - Sep, 2022	159,413	-1.9
Oct - Dec, 2022	140,976	+1.9
Jan - Mar, 2023	95,279	-25.5
Apr - Jun, 2023	75,686	-52.7
Jul - Sep, 2023	76,956	-51.7
Oct - Dec, 2023	82,386	-41.6
Jan - Mar, 2024	79,530	-16.5
Apr - Jun, 2024	90,675	+19.8
Jul - Sep, 2024	90,074	+17.0	-5,074	+85.5	-49,609	-97.8	-121.2	-66.7

All-Time High Quarterly Results

	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS
Record	162,534	40,423	46,610	32,960	83.0
Fiscal Year	Sep, 2021	Jun, 2019	Jun, 2022	Dec, 2020	Dec, 2020

Key Balance Sheet Figures

Fiscal Year	BPS	Equity Ratio	Total Asset	Equity	Retained Earnings	Interest-Bearing Debt Ratio	Announce	Accounting Standards
Mar, 2022	1,530.08	46.5	1,308,007	607,888	514,210	0.44	May 13, 2022	IFRS
Mar, 2023	1,023.80	35.8	1,134,742	406,749	280,999	0.82	May 15, 2023	IFRS
Mar, 2024	392.82	17.2	907,506	156,063	-22,665	2.68	May 14, 2024	IFRS
Apr - Sep, 2024	287.37	14.3	799,765	114,170	-13,254	3.41	Oct 30, 2024	IFRS

Sumitomo Pharma Co., Ltd.(4506) Financial Results